Close
Close

RNActive® Rabies Vaccine (CV7201) in Healthy Adults

Access Programs

Disease Information

Descriptive Information
Brief Title † RNActive® Rabies Vaccine (CV7201) in Healthy Adults
Official Title † Phase I Safety and Immunogenicity Trial of an Investigational RNActive® Rabies Vaccine (CV7201) in Healthy Adults
Brief Summary The purpose of this trial is to assess the safety and immunogenicity of an investigational RNActive® rabies vaccine (CV7201) in healthy adults.
Detailed Description
Study Phase Phase 1
Study Type † Interventional
Study Design †
Primary Outcome Measure † Incidence and severity of serious adverse events (SAEs)/adverse events (AEs) and local tolerability assessment of the vaccination site
Secondary Outcome Measure † The lowest CV7201 dose to elicit rabies VNTs ≥ 0.5 IE/ml
Condition † Rabies
Intervention † BiologicalCV7201 mRNA
Study Arms / Comparison Groups 80 µg CV7201 mRNA short Vaccination by injection on days 0, 7, 28. 160µg CV7201 mRNA short Vaccination by injection on days 0, 7, 28. 80 µg CV7201 mRNA long Vaccination by injection on days 0, 28, 56. 160 µg CV7201 mRNA long Vaccination by injection on days 0, 28, 56. 320 µg CV7201 mRNA long Vaccination by injection on days 0, 28, 56. 640 µg CV7201 mRNA long Vaccination by injection on days 0, 28. 200 µg CV7201 mRNA long Vaccination by injection on days 0, 28, 56. 400 µg CV7201 mRNA long Vaccination by injection on days 0, 28, 56.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Biological
Estimated Enrollment † 134
Start Date † October 2013
Completion Date March 2019
Primary Completion Date July 2018
Eligibility Criteria † Inclusion Criteria: 1. Healthy male and female volunteers aged 18 to 40 years inclusive 2. Compliant with protocol procedures and available for clinical follow-up through the last planned visit (V9) 3. Physical examination and laboratory results without clinically significant findings 4. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 5. Females: Negative human chorionic gonadotropin (HCG) pregnancy test (serum) for women presumed to be of reproductive potential on the day of enrolment 6. Females of childbearing potential must use acceptable methods of birth control during the trial and Follow-up period (from 6 weeks before the first administration of the test vaccine for the duration of the trial i.e., until the last planned visit (V9)). The following methods of birth control are acceptable when used consistently and correctly: established use of oral, injected or implanted hormonal methods of contraception; intrauterine devices (IUDs) or intrauterine systems (IUSs) with the exception of steel or copper wire; barrier methods of contraception (condom or occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository); true abstinence (periodic abstinence [e.g., calendar, ovulation, symptothermal and postovulation methods] and withdrawal are not acceptable). 7. Males must use reliable forms of contraception (barrier method with spermicidal agent or true abstinence) and must refrain from sperm donation during the trial and Follow-up period i.e., until the last planned visit (V9). Exclusion Criteria: 1. Use of any investigational or non-registered product (drug or vaccine) other than the trial vaccine within 4 weeks preceding the administration of the trial vaccine, or planned use during the trial period 2. Subject has received any other licensed vaccines within 4 weeks prior to the administration of the trial vaccine 3. Subject has received any investigational or licensed rabies vaccine previously 4. Intending to travel to regions/countries for which rabies vaccinations are recommended or where high risk of infections exists according to travel recommendations by the German Society of Tropical Medicine and International Health (DTG) during the trial and up to V9 (Day 91/120) Follow-up 5. Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. The use of inhaled and nasal steroids, as well as topical steroids outside the vaccination area, will be permitted 6. Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination 7. History of autoimmune disease 8. Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of the trial vaccine 9. Subject is taking chloroquine for malaria treatment or prophylaxis 10. Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness or fever ≥ 38 °C measured orally 11. Presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness (subjects with uncomplicated chronic diagnoses stable and treated for ≥ 3 months e.g., mild hypertension well-controlled with medication, may be enrolled - provided the condition and its therapy are known not to be associated with an immunocompromised state or an autoimmune disease 12. Major congenital defects 13. Known allergy to any component of the trial product i.e., protamine. This includes subjects with allergy to fish protein, diabetics with allergy to protamine-containing insulin, or post-vasectomy males 14. Known type I allergy to beta lactam antibiotics 15. Evidence of current alcohol or drug abuse 16. History of any neurological disorders or seizures, with the exception of febrile seizures during childhood 17. Seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) (except in subjects previously vaccinated against HBV) or hepatitis C virus (HCV) 18. Foreseeable non-compliance with protocol as judged by the Investigator 19. For females: Pregnancy or lactation 20. History of any life-threatening anaphylactic reactions. 21. Subjects with impaired coagulation in whom an IM injection is contraindicated.
Gender All
Ages 18 Years - 40 Years
Accepts Healthy Volunteers Accepts Healthy Volunteers
Contacts ††
Location Countries † Germany
Administrative Information
NCT ID † NCT02241135
Organization ID CV-7201-102
Secondary IDs †† 2013-002171-17
Responsible Party Sponsor
Study Sponsor † CureVac AG
Collaborators ††
Investigators † Principal Investigator: Franz-Josef von Sonnenburg, MD, Ludwig-Maximilians - University of Munich
Information Provided By
Verification Date May 2017
First Received Date † August 22, 2014
Last Updated Date May 30, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
187 views
Free Newsletter